Common use of Defined Terms Location Clause in Contracts

Defined Terms Location. Business Party Section 10.4 Business Program Section 10.4 CCPS Agreement Preamble CCPS Agreement Effective Date Preamble CCPS Agreement Term Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Celgene Indemnitees Section 16.7(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.11 Celgene Licensed Product In-Licensed IP Section 1.12 Celgene Other In-License Section 1.14 Celgene Regulatory Rights Section 1.15 Celgene Technology Section 1.16 Clinical Study Section 1.17 Co-Co In Licenses Section 8.1 Combination Product Section 1.36 Commercialization Section 1.18 Commercially Reasonable Efforts Section 1.19 Competitive Infringement Section 14.1 Control Section 1.20 Cost of Goods Sold or COGS Appendix F Covers Section 1.21 Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.23 EU Regulatory Event Section 1.24 Field Section 1.25 First Commercial Sale Section 1.26 First Indication Section 1.27 Fully Burdened Manufacturing Cost Appendix I GAAP Section 1.28 Gene Editing Section 1.31 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.32

Defined Terms Location. Business Clinical Study Section 1.16 Combination Product Section 1.32 Commercialization Section 1.17 Commercially Reasonable Efforts Section 1.18 Competitive Infringement Section 14.1 Control Section 1.19 Cost of Goods Sold or COGS Appendix F Covers Section 1.20 Development Cost Overage Section 4.3(c)(i) Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.21 EU Regulatory Event Section 1.22 Field Section 1.23 First Commercial Sale Section 1.24 First Indication Section 1.25 Fully Burdened Manufacturing Cost Appendix J GAAP Section 1.26 Gene Editing Section 1.27 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.28 Indemnification Claim Notice Section 16.6(c) Indemnified Party Section 10.4 Business Program 16.6(c) Information Request Section 10.4 CCPS 5.6(g) JGC Section 3.1(a) Joint IP Section 12.2 Licensed IP Section 1.29 Licensed Product Section 1.30 Losses Section 16.6(a) Major EU Countries Section 1.22 Manufacturing Section 1.31 Manufacturing and Supply Agreement Section 7.4(b)(ii) Marketing Costs Appendix F Master Collaboration Agreement Preamble CCPS Agreement Effective Date Preamble CCPS Agreement Term Milestone Event Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble 11.2(a) Milestone Payment Section 11.2(a) Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Celgene Indemnitees Section 16.7(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.11 Celgene Licensed Product In-Licensed IP Section 1.12 Celgene Other In-License Section 1.14 Celgene Regulatory Rights Section 1.15 Celgene Technology Section 1.16 Clinical Study Section 1.17 Co-Co In Licenses Section 8.1 Combination Product Section 1.36 Commercialization Section 1.18 Commercially Reasonable Efforts Section 1.19 Competitive Infringement Section 14.1 Control Section 1.20 Cost of Goods Sold or COGS Appendix F Covers Section 1.21 Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.23 EU Regulatory Event Section 1.24 Field Section 1.25 First Commercial Sale Section 1.26 First Indication Section 1.27 Fully Burdened Manufacturing Cost Appendix I GAAP Section 1.28 Gene Editing Section 1.31 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.32.

Defined Terms Location. Business Commercialization Section 1.15 Commercially Reasonable Efforts Section 1.16 Competitive Infringement Section 7.1 Control Section 1.17 Covers Section 1.18 Elected Candidate Appendix A EU Section 1.19 EU Regulatory Event Section 1.20 Field Section 1.21 First Commercial Sale Section 1.22 First Indication Section 1.23 Fully Burdened Manufacturing Cost Appendix H GAAP Section 1.24 Gene Editing Section 1.25 In-License Payment Section 1.26 Indemnification Claim Notice Section 9.6(c) Indemnified Party Section 10.4 Business Program 9.6(c) Joint IP Section 10.4 CCPS 5.2 License Agreement Preamble CCPS License Agreement Effective Date Preamble CCPS License Agreement Term Section 17.1 Celgene 10.1 Licensed IP Section 1.27 Licensed Product Section 1.28 Litigation Conditions Section 9.6(d)(i) Losses Section 9.6(a) Major EU Countries Section 1.20 Manufacturing Section 1.29 Manufacturing and Supply Agreement Section 2.4(c)(ii) Master Collaboration Agreement Preamble Celgene Corp Milestone Event Section 4.2 Milestone Payment Section 4.2 Modified Licensed Product Section 1.28 Net Sales Section 1.30 Original MCA Preamble Celgene Europe Party(ies) Preamble Patent Challenge Section 10.2(b) PHSA Section 7.2(f) Pivotal Study Section 1.31 Regulatory Exclusivity Period Section 1.32 Second Indication Section 1.33 Selling Party Section 1.34 Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Celgene Indemnitees Section 16.7(b) Celgene Licensed IP Section 1.9 Celgene Licensed Product In-License Section 1.11 Celgene Licensed Product In-Licensed IP Section 1.12 Celgene Other In-License Section 1.14 Celgene Regulatory Rights Section 1.15 Celgene Technology Section 1.16 Clinical Study Section 1.17 Co-Co In Licenses Section 8.1 Combination Product Section 1.36 Commercialization Section 1.18 Commercially Reasonable Efforts Section 1.19 Competitive Infringement Section 14.1 Control Section 1.20 Cost of Goods Sold or COGS Appendix F Covers Section 1.21 Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.23 EU Regulatory Event Section 1.24 Field Section 1.25 First Commercial Sale Section 1.26 First Indication Section 1.27 Fully Burdened Manufacturing Cost Appendix I GAAP Section 1.28 Gene Editing Section 1.31 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.32would be competitively harmful if publicly disclosed.

Defined Terms Location. Business Commercialization Section 1.15 Commercially Reasonable Efforts Section 1.16 Competitive Infringement Section 7.1 Control Section 1.17 Covers Section 1.18 Elected Candidate Appendix A EU Section 1.19 EU Regulatory Event Section 1.20 Field Section 1.21 First Commercial Sale Section 1.22 First Indication Section 1.23 Fully Burdened Manufacturing Cost Appendix H GAAP Section 1.24 Gene Editing Section 1.25 In-License Payment Section 1.26 Indemnification Claim Notice Section 9.6(c) Indemnified Party Section 10.4 Business Program 9.6(c) Joint IP Section 10.4 CCPS 5.2 License Agreement Preamble CCPS License Agreement Effective Date Preamble CCPS License Agreement Term Section 17.1 Celgene Preamble Celgene Corp Preamble Celgene Europe Preamble 10.1 Licensed IP Section 1.27 Licensed Product Section 1.28 Litigation Conditions Section 9.6(d)(i) Losses Section 9.6(a) Major EU Countries Section 1.20 Manufacturing Section 1.29 Manufacturing and Supply Agreement Section 2.4(c)(ii) Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) is the type that the registrant treats as private or confidential. Celgene Indemnitees Master Collaboration Agreement Preamble Milestone Event Section 16.7(b) Celgene Licensed IP 4.2 Milestone Payment Section 1.9 Celgene 4.2 Modified Licensed Product In-License Section 1.11 Celgene Licensed Product In-Licensed IP 1.28 Net Sales Section 1.12 Celgene Other In-License 1.30 Original MCA Preamble Party(ies) Preamble Patent Challenge Section 1.14 Celgene Regulatory Rights 10.2(b) PHSA Section 1.15 Celgene Technology Section 1.16 Clinical 7.2(f) Pivotal Study Section 1.17 Co-Co In Licenses 1.31 Regulatory Exclusivity Period Section 8.1 Combination Product Section 1.36 Commercialization Section 1.18 Commercially Reasonable Efforts Section 1.19 Competitive Infringement Section 14.1 Control Section 1.20 Cost of Goods Sold or COGS Appendix F Covers Section 1.21 Development & U.S. Commercialization Program Section 8.3(a) Distribution Costs Appendix F Elected Candidate Appendix A EU Section 1.23 EU Regulatory Event Section 1.24 Field Section 1.25 First Commercial Sale Section 1.26 First 1.32 Second Indication Section 1.27 Fully Burdened Manufacturing Cost Appendix I GAAP 1.33 Selling Party Section 1.28 Gene Editing Section 1.31 Gross Profit Appendix F Gross Sales Appendix F In-License Payment Section 1.321.34